Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
14 déc. 2023 08h00 HE
|
Phathom Pharmaceuticals
Amendment provides more favorable terms including a 14-month extension of the interest-only period and maturity date until December 2027Up to an additional $100 million in non-dilutive capital...
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
06 déc. 2023 08h00 HE
|
Phathom Pharmaceuticals
New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD, the largest subcategory of GERDJuly...
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
28 nov. 2023 08h00 HE
|
Phathom Pharmaceuticals
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available at major retail pharmacies and through BlinkRx.
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
09 nov. 2023 08h00 HE
|
Phathom Pharmaceuticals
VOQUEZNA® (vonoprazan) tablets approved by the U.S. Food and Drug Administration (FDA) for the treatment of Erosive GERD and relief of associated heartburn in adults, marking the first major...
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
01 nov. 2023 17h00 HE
|
Phathom Pharmaceuticals
FDA approval marks the first major innovation to the U.S. Erosive GERD market in over 30 yearsVOQUEZNA® met the primary endpoints and key secondary superiority endpoints in the pivotal Phase 3...
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
30 oct. 2023 08h00 HE
|
Phathom Pharmaceuticals
Planning for a December 2023 U.S. launch for H. pylori, together with the U.S. launch of vonoprazan for Erosive GERD, if approved FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
25 oct. 2023 08h01 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
26 sept. 2023 08h01 HE
|
Phathom Pharmaceuticals
Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
05 sept. 2023 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
21 août 2023 08h00 HE
|
Phathom Pharmaceuticals
Six-month stability data remain more than 10x below the acceptable intake limit set by the U.S. Food and Drug Administration (FDA) and continue to support the requested product shelf lifeSubmission of...